This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Arruda, M. Articles by Barlozzari, T. Search for Related Content PubMed PubMed Citation Articles by de Arruda, M. Articles by Barlozzari, T.

LU103793 (NSC D-669356): A Synthetic Peptide That Interacts with Microtubules and Inhibits Mitosis

BASF Bioresearch Corporation, Worcester, Massachusetts 01605-4314 [M. dA., C. A. C., C. M. N., C. G., T. B.], and BASF AG, D-67056 Ludwigshafen, Germany [B. J., A. H.]

LU103793 (NSC D-669356) is a new synthetic derivative of Dolastatin 15, an antiproliferative compound which was isolated from the mollusk Dolabella auricularia. Like Dolastatin 15, LU103793 is highly cytotoxic in vitro (IC₅₀ = 0.1 nM). To investigate the mechanism of action of LU103793, we used a combination of biochemical and cellular methods. Turbidity assays with bovine brain microtubules demonstrated that LU103793 inhibits microtubule polymerization in a concentration-dependent manner (IC₅₀ = 7 µM). Treatment with this compound also induced depolymerization of preassembled microtubules. Cell cycle analysis of tumor cell lines treated with LU103793 indicated a block in the G₂-M phase. At the cellular level, it induced depolymerization of microtubules in interphase cells and development of abnormal spindles and chromosome distribution in mitotic cells. Although these effects are very similar to the cellular alterations caused by vinblastine, LU103793 does not inhibit vinblastine binding to unpolymerized tubulin in vitro. Our results suggest that LU103793 exerts its cytotoxic activity primarily through disruption of microtubule organization.

¹ To whom requests for reprints should be addressed, at BASF Bioresearch Corporation, 100 Research Drive, Worcester, MA 01605.

Received 1/19/95. Accepted 5/12/95.

This article has been cited by other articles:

				R. Bai, M. C. Edler, P. L. Bonate, T. D. Copeland, G. R. Pettit, R. F. Luduena, and E. Hamel Intracellular Activation and Deactivation of Tasidotin, an Analog of Dolastatin 15: Correlation with Cytotoxicity Mol. Pharmacol., January 1, 2009; 75(1): 218 - 226. [Abstract] [Full Text] [PDF]

				A. Ray, T. Okouneva, T. Manna, H. P. Miller, S. Schmid, L. Arthaud, R. Luduena, M. A. Jordan, and L. Wilson Mechanism of Action of the Microtubule-Targeted Antimitotic Depsipeptide Tasidotin (Formerly ILX651) and Its Major Metabolite Tasidotin C-Carboxylate Cancer Res., April 15, 2007; 67(8): 3767 - 3776. [Abstract] [Full Text] [PDF]

				C.-L. Law, K. A. Gordon, B. E. Toki, A. K. Yamane, M. A. Hering, C. G. Cerveny, J. M. Petroziello, M. C. Ryan, L. Smith, R. Simon, et al. Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates Cancer Res., February 15, 2006; 66(4): 2328 - 2337. [Abstract] [Full Text] [PDF]

				S. Ebbinghaus, E. Rubin, E. Hersh, L. D. Cranmer, P. L. Bonate, R. J. Fram, A. Jekunen, S. Weitman, and L. A. Hammond A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors Clin. Cancer Res., November 1, 2005; 11(21): 7807 - 7816. [Abstract] [Full Text] [PDF]

				T. L. Simmons, E. Andrianasolo, K. McPhail, P. Flatt, and W. H. Gerwick Marine natural products as anticancer drugs Mol. Cancer Ther., February 1, 2005; 4(2): 333 - 342. [Abstract] [Full Text] [PDF]

				M. L. Amador, J. Jimeno, L. Paz-Ares, H. Cortes-Funes, and M. Hidalgo Progress in the development and acquisition of anticancer agents from marine sources Ann. Onc., November 1, 2003; 14(11): 1607 - 1615. [Full Text] [PDF]

				Y.-H. Ling, J.-D. Jiang, J. F. Holland, and R. Perez-Soler Arsenic Trioxide Produces Polymerization of Microtubules and Mitotic Arrest before Apoptosis in Human Tumor Cell Lines Mol. Pharmacol., September 1, 2002; 62(3): 529 - 538. [Abstract] [Full Text] [PDF]